Olema Pharmaceuticals inc
(NAS:OLMA)
$
11.62
0.21 (1.84%)
Market Cap: 649.95 Mil
Enterprise Value: 403.18 Mil
PE Ratio: 0
PB Ratio: 2.75
GF Score: 41/100 - Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Olema Pharmaceuticals Inc Palazestrant Phase 2 Monotherapy Clinical Update Presentation TranscriptOct 23, 2023
- Olema Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Olema Pharmaceuticals Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Olema Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Olema Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Olema Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 23, 2023
- Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Olema Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Olema Pharmaceuticals Inc at Jefferies London Healthcare Conference TranscriptNov 16, 2022
- Olema Pharmaceuticals Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- Olema Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Olema Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) TranscriptApr 14, 2022
- Olema Pharmaceuticals Inc to Review the Phase 1 Clinical Data for OP-1250 TranscriptNov 30, 2021
- Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
Olema Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022 / 03:30PM GMT
Release Date Price:
$3.08
(-5.52%)
Arlinda Lee
Canaccord Genuity LLC - Analyst
Good morning. My name is Arlinda Lee and I'm a senior analyst on Canaccord's biotech team. I'm pleased Olema's President and Chief Executive Officer, Sean Bohen, is joining us today for a fireside chat to talk about Olema's dual SERD CERAN OP-1250 and its clinical development. Sean, welcome.
Sean Bohen
Olema Pharmaceuticals, Inc. - President and CEO
Thank you, Arlinda, and thank you for having me.
Questions & Answers
Arlinda Lee
Canaccord Genuity LLC - Analyst
Great. Let's start talking about Olema's 1250. It's currently in monotherapy dose escalation -- dose expansion at the 60 milligram and 120 milligram doses. How do you -- what are the criteria that you're going to use to select the recommended Phase 2 dose and when do you expect to do that?
Sean Bohen
Olema Pharmaceuticals, Inc. - President and CEO
Yeah. So the criteria mainly will be an expansion of tolerability and an expansion of our information with
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)